Comparative Pharmacology
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE versus TRANDATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE versus TRANDATE.
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE vs TRANDATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dorzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor secretion by inhibiting carbonic anhydrase in the ciliary processes. Timolol is a non-selective beta-adrenergic receptor antagonist that reduces aqueous humor production by blocking beta-2 adrenergic receptors in the ciliary epithelium.
Competitive antagonist at beta-1 and beta-2 adrenergic receptors; also blocks alpha-1 adrenergic receptors, causing vasodilation.
One drop of the fixed combination (dorzolamide 22.26 mg/mL, timolol 6.83 mg/mL) in the affected eye(s) every 12 hours.
Initial: 100 mg orally twice daily, titrate to 200-400 mg twice daily; maximum 2400 mg/day. Alternatively, 20 mg IV bolus over 2 minutes, then 40-80 mg IV at 10-minute intervals as needed; IV infusion: 2 mg/min, titrate to response.
None Documented
None Documented
Dorzolamide: ~4 months but accumulates in RBCs; terminal half-life ~4-5 months due to binding to carbonic anhydrase. Timolol: ~4-6 hours.
Terminal elimination half-life is approximately 6-8 hours in healthy individuals, but may be prolonged in patients with hepatic impairment or severe renal dysfunction (up to 12-16 hours).
Dorzolamide: primarily renal (approx. 80% unchanged), with minor biliary/fecal elimination. Timolol: renal (15-20% unchanged) and extensive hepatic metabolism with fecal excretion.
Labetalol is extensively metabolized in the liver via glucuronidation; less than 5% of the dose is excreted unchanged in urine. Approximately 55-60% of metabolites are excreted renally, and about 30% in feces via biliary secretion.
Category A/B
Category C
Beta-Blocker
Beta-Blocker